GSK Pharma - Long-Term Outlook Remains Positive: HDFC Securities Retail Research Initiates Coverage
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
HDFC Securities Retail Research Report
GlaxoSmithKline Pharmaceuticals Ltd. is one of the leading multi national pharma companies with a market share of ~3% in the Indian Pharma market.
GSK Pharma is the market leader in most of the therapeutic categories in which it operates, its leading brands include Augmentin (number one anti-infective brand), Calpol, Betnovate, T Bact, Betnesol, Ceftum, Cobadex CZS, Seretide, Phexin, Eltroxin and Neosporin.
In Indian private channel vaccine market the company holds dominant position with Synflorix being second largest vaccine brand (annual sales of Rs 200 crore).
Overall, GSK Pharma markets nine vaccines in the domestic market and this contributed ~24% of sales in FY21.
Its FY21 performance was optically muted, mainly due to high Zinetac (Ranitidine) business in FY20 which fell in FY21 due to global recall.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.